Your browser doesn't support javascript.
loading
Fosfomycin: a good alternative drug for prostate biopsy prophylaxis the results of a prospective, randomized trial with respect to risk factors
Kisa, Erdem; Altug, Mustafa Ugur; Gurbuz, Oguz Alp; Ozdemir, Harun.
  • Kisa, Erdem; Tepecik Education and Research Hospital. Department of Urology. Izmir. TR
  • Altug, Mustafa Ugur; Tepecik Education and Research Hospital. Department of Urology. Izmir. TR
  • Gurbuz, Oguz Alp; Tepecik Education and Research Hospital. Department of Urology. Izmir. TR
  • Ozdemir, Harun; Tepecik Education and Research Hospital. Department of Urology. Izmir. TR
Int. braz. j. urol ; 43(6): 1068-1074, Nov.-Dec. 2017. graf
Artículo en Inglés | LILACS | ID: biblio-892916
ABSTRACT
ABSTRACT

Purpose:

To determine the risk factors and the efficiency of rectal swab samples to prevent infectious complications in prostate biopsy, and compare fosfomycin with ciprofloxacin use in prophylaxis. Materials and

Methods:

Between May and October 2014, pre-biopsy risk factors and their effect in ciprofloxacin and fosfomycin prophylaxis were determined. Pre-biopsy urinalysis, urine culture and rectal swab samples were obtained from all of the patients. Rectal swabs were obtained upon admission, and biopsy was performed in the following 3-7 days. The place of rectal swab samples and efficiency of fosfomycin use was evaluated.

Results:

Pre-biopsy rectal swabs were obtained from 110 patients who revealed 60.9% fluoroquinolone resistance (FQR), and 32.7% fluoroquinolone sensitivity (FQS). Fosfomycin resistance was present in 3 patients. Ciprofloxacin use in last 6 months was the only risk factor for FQR. Antibiotic prophylaxis was given to both groups with and without risk factors, according to swab results, and no infective complications were observed. Among the group where fosfomycin was used empirically, one patient had an infection needing hospitalization, however this constitutes no statistical difference between the Group that fosfomycin used empirically or according to swab results (p=0.164).

Conclusions:

In prostate biopsy prophylaxis, ciprofloxacin may be used liberally in patients without risk factors, but it should be given according to the rectal swab results in the patients with risk, and fosfomycin may be used independently of risk factors and rectal swab results.
Asunto(s)


Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Próstata / Neoplasias de la Próstata / Profilaxis Antibiótica / Biopsia Guiada por Imagen / Fosfomicina / Antibacterianos Tipo de estudio: Ensayo Clínico Controlado / Estudio de etiología / Estudio observacional / Factores de riesgo Límite: Humanos / Masculino Idioma: Inglés Revista: Int. braz. j. urol Asunto de la revista: Urología Año: 2017 Tipo del documento: Artículo País de afiliación: Turquía Institución/País de afiliación: Tepecik Education and Research Hospital/TR

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Próstata / Neoplasias de la Próstata / Profilaxis Antibiótica / Biopsia Guiada por Imagen / Fosfomicina / Antibacterianos Tipo de estudio: Ensayo Clínico Controlado / Estudio de etiología / Estudio observacional / Factores de riesgo Límite: Humanos / Masculino Idioma: Inglés Revista: Int. braz. j. urol Asunto de la revista: Urología Año: 2017 Tipo del documento: Artículo País de afiliación: Turquía Institución/País de afiliación: Tepecik Education and Research Hospital/TR